Compare Enact Holdings Inc (ACT) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enact Holdings Inc vs Medpace Holdings Inc — how do they compare? Enact Holdings Inc trades at $49.44 (market cap $6.75B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 2.5× Enact Holdings Inc's market cap, and Enact Holdings Inc pays a 1.95% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| ACT | MEDP | |
|---|---|---|
Market Cap | $6.75B | $16.90B |
Sector | Technology | Technology |
52-Week High | $49.12 | $620.59 |
52-Week Low | $34.93 | $393.42 |
Enterprise Value | $7.05B | $16.52B |
Dividend Yield | 1.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $49.38, up 1.81% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows strong profitability with a net income margin of 54.51% and ROE of 12.87%, supported by recent earnings beats. Analysts have a consensus price target of $49.00, with 37.5% buy ratings. Recent news highlights Q2 2026 earnings beating estimates and dividend announcements.
The outlook is cautiously optimistic given solid fundamentals and positive earnings trends, but risks include potential overvaluation with a P/S of 5.65 and technical overbought conditions. Investor sentiment is mixed with no sell ratings, yet the stock faces execution risks in a competitive insurance market.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
